The case for eteplirsen: Paving the way for precision medicine.

doi:10.1016/j.ymgme.2016.04.001

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The case for eteplirsen: Paving the way for precision medicine.

Molecular genetics and metabolism - 1 Jun 2016

Miceli M Carrie, Nelson Stanley F

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Intravenous
Share to Dystrophin
Share to Morpholinos
Share to Muscular Dystrophy, Duchenne

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Open Reading Frames

Share to Precision Medicine

Share to Rare Diseases

Share to United States Food and Drug Administration

Source

Open in PubMed

Identifiers

PMID: 27102846
DOI: 10.1016/j.ymgme.2016.04.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The case for eteplirsen: Paving the way for precision medicine.PMID 27102846Read ↗

Precision medicine with MET exon 14: a partial success.Semantic proximity Read ↗

Precision Medicine for COVID-19: Phenotype Anarchy or Promise Realized?Semantic proximity Read ↗

Laying the foundations for personalized medicines.Semantic proximity Read ↗

Milestones of Precision Medicine: An Innovative, Multidisciplinary OverviewSemantic proximity Read ↗

Therapeutics: a glimpse of the future.Semantic proximity Read ↗

Pharmacogenomics: time to rethink its role in precision medicine.Semantic proximity Read ↗

Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations.Semantic proximity Read ↗

KRAS: Druggable at Last.Semantic proximity Read ↗

Personalized therapy.Semantic proximity Read ↗

Personalized medicine: Special treatment.Semantic proximity Read ↗

23andMe and the FDA.Semantic proximity Read ↗

Personalized medicine gets practical.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.